Home > Resources > Whitepapers > A Case for Small Cap Investing: Biotech

A Case for Small Cap Investing: Biotech

In this paper, we sought to lay out the rationale for investing in small cap biotech. There are two key drivers of stock performance of small cap biotech: clinical data and acquisitions. As clinical data must be analyzed on a case-by-case basis, we have focused our efforts in this paper on factors that will drive M&A in this space. We have also examined the forces that worked to get us to the point we are today. We have arrived at four principles that we believe frame the discussion around the future of M&A. The discussion begins by taking a deep dive into the desperation being felt by the potential acquirers.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

LeaderStat

LeaderStat is a national recruiting and consulting firm dedicated to the healthcare industry. We place top performers in key roles on an interim, retained and contingency basis. Our consulting division assists clients in a variety of operational areas including clinical reimbursement, financial and operational analysis, ACO integration and alignment, survey readiness and many other areas critical to our client’s success.

OTHER WHITEPAPERS
news image

Strengthening Engagement and Influence with Key Decision Makers

whitePaper | January 5, 2023

This report follows up on the jointly hosted Pharmaforce and elandas webinar which took place on July, 12, 2016, featuring contributions from participating industry leaders who formed the expert panel, as well as the live contributions of the audience of healthcare sales and marketing professionals.

Read More
news image

National Council for Prescription Drug Programs

whitePaper | May 12, 2022

This document is Copyright © 2022 by the National Council for Prescription Drug Programs (NCPDP). It may be freely redistributed in its entirety provided this copyright notice is not removed.

Read More
news image

The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

whitePaper | April 16, 2020

Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing unexpected cost increases for payers and consumers, and spurring an investigation by the United States Congress. High generic drug prices have had an adverse effect on almost everyone in the pharmaceutical supply chain. Consumers face higher co-pays and prices and health plans are dealing with higher drug spend. Physicians are finding the need to prescribe alternative drug therapies while dealing with angry patients.

Read More
news image

Getting serious about serialization: A comprehensive look at thelegislation shaping U.S. pharmaceutical supply chains

whitePaper | October 7, 2022

The Drug Supply Chain Security Act is one component of the DQSA. This particular act requires the FDA to implement a national track-and-trace system by which manufacturers must affix product identifiers (barcodes) to each package of product that is introduced into the supply chain.

Read More
news image

Characterization of Protein Aggregates and Other Particles in Biopharmaceuticals

whitePaper | July 8, 2022

Particulates are ubiquitous in parenteral drug products and remain a concern throughout their development and production1–3. These particles must be monitored to satisfy.

Read More
news image

Multi-channel clinical trial recruitment technology checklist

whitePaper | August 8, 2022

Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.

Read More

Strengthening Engagement and Influence with Key Decision Makers

whitePaper | January 5, 2023

This report follows up on the jointly hosted Pharmaforce and elandas webinar which took place on July, 12, 2016, featuring contributions from participating industry leaders who formed the expert panel, as well as the live contributions of the audience of healthcare sales and marketing professionals.

Read More

National Council for Prescription Drug Programs

whitePaper | May 12, 2022

This document is Copyright © 2022 by the National Council for Prescription Drug Programs (NCPDP). It may be freely redistributed in its entirety provided this copyright notice is not removed.

Read More

The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

whitePaper | April 16, 2020

Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing unexpected cost increases for payers and consumers, and spurring an investigation by the United States Congress. High generic drug prices have had an adverse effect on almost everyone in the pharmaceutical supply chain. Consumers face higher co-pays and prices and health plans are dealing with higher drug spend. Physicians are finding the need to prescribe alternative drug therapies while dealing with angry patients.

Read More

Getting serious about serialization: A comprehensive look at thelegislation shaping U.S. pharmaceutical supply chains

whitePaper | October 7, 2022

The Drug Supply Chain Security Act is one component of the DQSA. This particular act requires the FDA to implement a national track-and-trace system by which manufacturers must affix product identifiers (barcodes) to each package of product that is introduced into the supply chain.

Read More

Characterization of Protein Aggregates and Other Particles in Biopharmaceuticals

whitePaper | July 8, 2022

Particulates are ubiquitous in parenteral drug products and remain a concern throughout their development and production1–3. These particles must be monitored to satisfy.

Read More

Multi-channel clinical trial recruitment technology checklist

whitePaper | August 8, 2022

Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.

Read More
More Whitepapers

Spotlight

LeaderStat

LeaderStat is a national recruiting and consulting firm dedicated to the healthcare industry. We place top performers in key roles on an interim, retained and contingency basis. Our consulting division assists clients in a variety of operational areas including clinical reimbursement, financial and operational analysis, ACO integration and alignment, survey readiness and many other areas critical to our client’s success.

Events

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference